Amylyx Pharmaceuticals Inc
AMLXHealthcare|Drug Manufacturers - Specialty & Generic|USA
$17.77
-0.60 (-3.29%)
Tangible Book
$2.46
About
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Stock Price
+140.5%(1Y)
Pipeline Summary
13 total trials2
Phase 1
7
Phase 2
5
Phase 3
0
Phase 4
Completed: 6Unknown: 1AVAILABLE: 1APPROVED_FOR_MARKETING: 1Active: 3Recruiting: 1
Active Trials (4)
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
NCT05021536Amyotrophic Lateral Sclerosis
Phase 3Active
Enrollment: 664 participants
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165ALS
Phase 1Recruiting
Enrollment: 48 participants
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Phase 3Active
Enrollment: 75 participants
AMX0035 in Adult Patients With Wolfram Syndrome
NCT05676034Wolfram Syndrome
Phase 2Active
Enrollment: 12 participants
BioScore
4.5/10
Cautious
Ownership
Recent Insider Trades
Firestone KarenBUY
2026-05-213,800 shares @ $13.51
FRATES JAMES MSELL
2026-03-027,909 shares @ $14.52
Mazzariello GinaSELL
2026-03-026,844 shares @ $14.52
Klee Justin B.SELL
2026-03-0229,282 shares @ $14.47
Cohen Joshua BSELL
2026-03-0229,282 shares @ $14.48
Recent News
2026-07-03 17:00:03
2026-06-25 14:40:58
2026-06-23 12:33:01
2026-06-23 12:00:08
Data last updated: Jul 13, 2026, 12:44 PM